Replies to post #39755 on Bergamo Acquisition Corp. (BGMO)

[HighYieldInvestments]

VistaGen Therapeutics Board of Directors APPROVED RECENT TRANSACTION

Jon S. Saxe,
Chairman

Brian J. Underdown, Ph.D.,
Director

H. Ralph Snodgrass, Ph.D.,
Founder, President and Chief Scientific Officer

Shawn K. Singh, J.D.
Chief Executive Officer

Management Team

Shawn K. Singh, J.D.
Chief Executive Officer, Director

H. Ralph Snodgrass, Ph.D.
Founder, President and Chief Scientific Officer, Director

Jerrold D. Dotson, CPA
Acting Chief Financial Officer

A. Franklin Rice, MBA
VP of Corporate Development, Secretary

Scientific Advisory Board

Gordon Keller, Ph.D.
Chairman, Director, McEwen Centre for Regenerative Medicine, University Health Network
DIRECTOR'S OF VSTA APPROVED RECENT TRANSACTION LIKE IT OR NOT

[old man river]

We need to take a pinch of salt here folks!

BGMO does have an established record of making announcements of fundings which are closely followed by press releases of the acquisition of 60% or more of leading edge capital starved businesses. Unfortunately, none of them have closed, so says the accountant.

Even those that did not close, there is some evidence of extensions to the share purchase agreements but they too never did close.

So, in the VSTA story, we have seen an amendment to the payment schedule and some missed dates. Based on the past experience, this should raise some concern with their management.

Suppose for a moment if BGMO does deliver the $ 36 million as promised, will this be enough to support VSTA for say a few years before all of the FDA and marketing activities are complete? My very cursory reading suggests that it could even be dicey. More share issuances at VSTA would likely be needed.